课题基金 / 基金详情

Predictive chemometrics modelling for enhanced robustness of integrated continuous biomanufacturing processes

Predictive chemometrics modelling for enhanced robustness of integrated continuous biomanufacturing processes
预测化学计量学建模可增强集成连续生物制造过程的稳健性
批准号:
1953111
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2017
资助国家:
英国
项目状态:
已结题
起止时间:
2017 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
拟议的博士项目将解决为生物制药蛋白(如双特异性抗体)的新模式开发强大的连续制造工艺的挑战。连续生物处理正在该行业内重新兴起。它有可能提高产品质量,并从根本上减少生产能力和设施占地要求。此外,一些人认为,连续加工能够更好地解决市场需求的不确定性,并将技术转让风险降至最低。需要一种严格的方法来评估采用连续生物处理的产品对产品质量、过程稳健性和组合管理的影响,以确定新模式商业化的最佳途径。伦敦大学学院的生化工程系在应对这一挑战方面处于有利地位,因为它率先开发了包括生物过程优化和化学计量学在内的决策工具。这些工具将使集成单元操作的超缩小研究能够更好地模拟大规模连续生物过程,增强对其的理解,将解决有效的生物过程设计,投资组合管理和能力规划决策。该项目旨在创建实验和预测建模工具,以评估和优化生物制药端到端连续生物加工的新想法。将评价连续加工维持和控制生物制剂产品质量的潜力。MedImmune正在评估与多柱连续色谱系统相关联的ATF灌注培养在实验规模上集成连续生物处理的潜力。与连续捕获色谱相关联的灌注培养集成缩小平台的开发,将能够进行更高通量的实验,以探索连续上游和下游处理步骤中关键工艺参数对质量和性能的影响。首先,将分析现有灌注培养模拟物(例如高通量微型生物反应器(例如ambr, Sartorius)和自旋管)和连续色谱模拟物(例如1ml柱)的能力和局限性。这将形成缩小模型的新设计的基础,克服现有方法的局限性,并将足够的传感器集成到设备中,例如用于细胞培养的pH值和溶解氧。集成的缩小平台的性能将通过与MedImmune的连续色谱相连接的实验规模(5L)灌注运行进行验证。集成连续生物过程的实验数据生成按比例缩小的灌注模拟将与连续捕获色谱模拟相关联,用于将细胞培养性能与下游性能联系起来的实验数据生成。灌注培养的关键工艺参数(如饲料流量)和连续色谱(如停留时间,流量)将通过风险分析确定。确定每个实验中要测量的关键性能输出(如生产率)和质量属性(如糖基化、电荷异构体、产品相关杂质)。这些输入和输出将构成DoE实验的基础,使用来自MedImmune的工业相关细胞系表达新模式(如双特异性抗体)。生物过程建模和连续过程控制的化学计量学实验数据将用于建立预测的因果模型,该模型将关键工艺参数(例如灌注饲料流量)与关键质量属性(例如聚合)和性能指标(例如灌注培养效率,色谱产率)联系起来,使用先进的化学计量学/多变量数据分析技术。将探讨连续运行的时间影响;米
英文摘要
The proposed PhD project will address the challenge of developing robust continuous manufacturing processes for new modalities of biopharmaceutical proteins such as bispecific antibodies. Continuous bioprocessing is experiencing a resurgence within the sector. It has the potential to enhance product quality and radically reduce capacity and facility footprint requirements for manufacture. Furthermore, continuous processing is considered by some to be better able to address market demand uncertainties and minimise technology transfer risks. A rigorous approach to assessing the impact of introducing products adopting continuous bioprocessing on product quality, process robustness and portfolio management is required to determine the best route to commercialisation of new modalities. The department of Biochemical Engineering at UCL is well-placed to address this challenge as it has pioneered the development of decisional tools comprising bioprocess optimisation and chemometrics. These tools will enable ultrascale-down studies of integrated unit operations to better mimic large scale continuous bioprocesses, the enhanced understanding of which will address effective bioprocess design, portfolio management and capacity planning decisions.This project aims to create experimental and predictive modelling tools to assess and optimise novel ideas for end-to-end continuous bioprocessing of biopharmaceuticals. The potential of continuous processing to maintain and control product quality of biologics will be evaluated.MedImmune is evaluating the potential of integrated continuous bioprocessing at bench scale with ATF perfusion culture linked to multi-column continuous chromatography systems. The development of an integrated scale-down platform of perfusion culture linked to continuous capture chromatography will enable higher throughput experiments to be performed to explore the impact of critical process parameters in the continuous upstream and downstream processing steps on quality and performance. Initially, analysis of the capabilities and limitations of existing perfusion culture mimics (e.g. with high throughput mini-bioreactors (eg ambr, Sartorius) and spin tubes) and continuous chromatography mimics (e.g. 1ml columns) will be carried out. This will form the basis of novel designs of scale-down mimics that overcome limitations with existing methodologies and have sufficient sensors integrated into the devices for e.g. pH and dissolved oxygen for cell culture. The performance of the integrated scale-down platform will be validated with bench scale (5L) perfusion runs linked to continuous chromatography at MedImmune. Experimental data generation for integrated continuous bioprocessesThe scale down perfusion mimics will be linked to continuous capture chromatography mimics for experimental data generation linking cell culture performance with downstream performance. Key process parameters in perfusion culture (e.g. feed flowrates) and continuous chromatography (e.g. residence time, flowrates) will be identified using risk analysis. Key performance outputs (e.g. productivities) and quality attributes (e.g. glycosylation, charge isoforms, product-related impurities) to measure in each experiment will be identified. These inputs and outputs will form the basis for DoE experimentation using industrially relevant cell lines from MedImmune expressing novel modalities eg bispecific antibodies. Chemometrics for bioprocess modelling and control of continuous processesExperimental data will be used to build predictive cause-and-effect models that link critical process parameters (e.g. perfusion feed flowrates) to critical quality attributes (e.g. aggregates) and performance metrics (e.g. perfusion culture productivity, chromatography yield) using advanced chemometrics / multivariate data analysis techniques. The temporal impacts of continuous operation will be explored; m
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Advanced control strategies in CHO perfusion culture for automation and optimisation of productivity and cell growth
CHO 灌流培养中的先进控制策略,可实现生产力和细胞生长的自动化和优化
DOI: --
发表时间: 2019
期刊:
影响因子: --
作者: [Roth F]
通讯作者: Roth F
海外基金